Brilinta-话题@MedSci

#Brilinta#

10篇内容 | 2386人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1249468, encodeId=8a491249468a5, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a>, objectTitle=JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！, objectType=article, longId=265003, objectId=1a842650033c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211212/1639276677459_2299762.jpg, objectUrl=/article/show_article.do?id=1a842650033c, replyNumber=0, likeNumber=87, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a842650033c, moduleTitle=JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a842650033c)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249467, encodeId=f30a124946e9e, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a><a href='/topic/show?id=5a626408e66' target=_blank style='color:#2F92EE;'>#氯吡格雷#</a>, objectTitle=JAMA Neurology：阿司匹林基础上小中风和TIA患者应该选择替格瑞洛or氯吡格雷？, objectType=article, longId=732825, objectId=54bfe3282519, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220719/1658234639014_2299762.jpg, objectUrl=/article/show_article.do?id=54bfe3282519, replyNumber=0, likeNumber=76, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54bfe3282519, moduleTitle=JAMA Neurology：阿司匹林基础上小中风和TIA患者应该选择替格瑞洛or氯吡格雷？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54bfe3282519)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249466, encodeId=2dc1124946632, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a>, objectTitle=Stroke：高血压对替卡格雷-阿司匹林与氯吡格雷-阿司匹林治疗卒中效果的影响, objectType=article, longId=729042, objectId=e522e2904223, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220609/1654774243269_1739456.jpg, objectUrl=/article/show_article.do?id=e522e2904223, replyNumber=0, likeNumber=90, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e522e2904223, moduleTitle=Stroke：高血压对替卡格雷-阿司匹林与氯吡格雷-阿司匹林治疗卒中效果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e522e2904223)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249465, encodeId=65c31249465a8, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a>, objectTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, objectType=article, longId=65585, objectId=4f7365585cc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201603/20160326140558742.png, objectUrl=/article/show_article.do?id=4f7365585cc, replyNumber=0, likeNumber=65, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7365585cc, moduleTitle=阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f7365585cc)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249464, encodeId=cb4f124946416, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）联合<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>用于<a href='/topic/show?id=77c33081e40' target=_blank style='color:#2F92EE;'>#冠心病#</a><a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>，这些高风险人群，可能获益会更多一些, objectTitle=替卡格雷联合阿司匹林显著降低冠心病和2型糖尿病患者的心血管事件风险, objectType=article, longId=178639, objectId=33d51e8639b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201909/20190902161749110.jpeg, objectUrl=/article/show_article.do?id=33d51e8639b9, replyNumber=0, likeNumber=111, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33d51e8639b9, moduleTitle=替卡格雷联合阿司匹林显著降低冠心病和2型糖尿病患者的心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33d51e8639b9)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249463, encodeId=938d124946392, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=ab99522007b' target=_blank style='color:#2F92EE;'>#急性冠脉综合征#</a>, objectTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, objectType=article, longId=183283, objectId=416a18328369, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201911/20191119194926468.jpg, objectUrl=/article/show_article.do?id=416a18328369, replyNumber=0, likeNumber=73, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=416a18328369, moduleTitle=阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=416a18328369)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249462, encodeId=4841124946220, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a>, objectTitle=阿斯利康的Brilinta可改善轻度急性缺血性卒中或短暂性脑缺血发作后的预后, objectType=article, longId=186836, objectId=03d51868368d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/202001/20200127205351701.jpeg, objectUrl=/article/show_article.do?id=03d51868368d, replyNumber=0, likeNumber=0, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03d51868368d, moduleTitle=阿斯利康的Brilinta可改善轻度急性缺血性卒中或短暂性脑缺血发作后的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03d51868368d)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249461, encodeId=b79012494619f, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a>, objectTitle=FDA批准替格瑞洛用于降低卒中风险, objectType=article, longId=203197, objectId=ad5920319eea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201009/571711934ee048f8b6e5cbb4148e8fd8.jpg, objectUrl=/article/show_article.do?id=ad5920319eea, replyNumber=0, likeNumber=64, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad5920319eea, moduleTitle=FDA批准替格瑞洛用于降低卒中风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad5920319eea)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249460, encodeId=9b1e12494600d, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）, objectTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, objectType=article, longId=203553, objectId=aa6a203553c0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201113/14941593f7634df6bca8c411040c7916.jpg, objectUrl=/article/show_article.do?id=aa6a203553c0, replyNumber=0, likeNumber=43, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6a203553c0, moduleTitle=III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6a203553c0)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1249458, encodeId=c7021249458a0, content=<a href='/topic/show?id=eb103e35fe' target=_blank style='color:#2F92EE;'>#Brilinta#</a>（即<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>）联合<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>：III期研究证实继发性<a href='/topic/show?id=fa10e93597f' target=_blank style='color:#2F92EE;'>#缺血性卒中#</a><a href='/topic/show?id=ec01226163e' target=_blank style='color:#2F92EE;'>#中风#</a>死亡率降低17%, objectTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, objectType=article, longId=197637, objectId=bcef19e637ac, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020716/1594895387673_5085975.jpg, objectUrl=/article/show_article.do?id=bcef19e637ac, replyNumber=0, likeNumber=110, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcef19e637ac, moduleTitle=Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcef19e637ac)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 梅斯话题小助手

Brilinta

2020-05-29

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中#

JAMA子刊：阿司匹林基础上，替格瑞洛vs氯吡格雷DAPT治疗中风的效果无差！

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中##氯吡格雷#

JAMA Neurology：阿司匹林基础上小中风和TIA患者应该选择替格瑞洛or氯吡格雷？

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中#

Stroke：高血压对替卡格雷-阿司匹林与氯吡格雷-阿司匹林治疗卒中效果的影响

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中#

阿斯利康心血管药Brilinta未能达到新适应症III期临床主要终点

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）联合#阿司匹林#用于#冠心病##糖尿病#，这些高风险人群，可能获益会更多一些

替卡格雷联合阿司匹林显著降低冠心病和2型糖尿病患者的心血管事件风险

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#急性冠脉综合征#

阿斯利康的P2Y12受体拮抗剂Brilinta单一疗法可降低急性冠状动脉综合症患者的出血风险

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中#

阿斯利康的Brilinta可改善轻度急性缺血性卒中或短暂性脑缺血发作后的预后

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）#缺血性卒中#

FDA批准替格瑞洛用于降低卒中风险

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）

III期临床证实替格瑞洛联合阿司匹林：将高危亚组患者中风和死亡率降低27%

2022-09-17

(审核中...)

前往app查看评论内容

#Brilinta#（即#替格瑞洛#）联合#阿司匹林#：III期研究证实继发性#缺血性卒中##中风#死亡率降低17%

Brilinta联合阿司匹林：III期研究证实继发性中风死亡率降低17%

2022-09-17

科室
- - 订阅+
  - 更多科室
工具
服务